Skip to content
Biodatica
Start free

RayzeBio, Inc.

Iowa City, Iowa

OncologyPhase III
Compare Sign in to watch

What changed

Phase I trial registered: Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

5w agoTrial registeredJun 9, 2026Source filing (opens the source filing in a new tab)

Momentum

80no change

Momentum 80 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

542 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Dec 3, 2025

    GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor, Somatostatin Receptor · RECRUITING · sponsor: RayzeBio, Inc. · Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

    ClinicalTrials.gov · NCT07165132 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Mar 24, 2022

    GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET · RECRUITING · sponsor: RayzeBio, Inc. · Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    ClinicalTrials.gov · NCT05477576 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources